The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue SUPPL. 2, 2007, Pages

  Watkins, David ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

EPIC; EVEREST; Monoclonal antibodies; Oxaliplatin; Panitumumab; Refractory disease

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HUMAN; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PAIN; PROTEIN EXPRESSION; REVIEW; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 37049006749     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.s.002     Document Type: Article

References (46)

1. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44:1002-7.
2. Gill G, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984; 259:7755-60.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
4. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20(18 suppl):1s-13s.
5. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21:105-15.
6. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92:1331-46.
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
8. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-560.
9. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53:4637-42.
10. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8:994-1003.
11. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract 7).
12. Saltz LB, Meropol NJ, Loehrer PJ, Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses rhe epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
13. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorecral cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-10.
14. Saltz L. In Reply: 10.1200/JCO.2005.05.354. J Clin Oncol 2005; 23:923-4.
15. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13:1552-61.
16. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564-71.
17. Arends R, Yang BB, Schwab G, et al. Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients. J Clin Oncol 2005; 23(16 suppl):214s (Abstract 3089).
18. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23(16 suppl):251s (Abstract 3520).
19. Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. Presented at: the 2007 ASCO Gastrointestinal Cancers Symposium; January 19-21; Orlando, FL. Abstract 237.
20. Wilke H, Glynne-Jones R, Thaler J, et al. MABEL - A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3549).
21. Jonker D, O'Callaghan C, et al. Randomized phase III trial of cetuximab + best supportive care (BSC) versus BSC alone in patients with pretreated metastatic EGFR-positive colorectal cancer (NCIC CTG CO.17). Presented at: the 2007 Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract LB1.
22. Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007; 18:305-10.
23. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002; 21:135a (Abstract 536).
24. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450-6.
25. Rougier P, Raoul J-L, Van Laethem J-L, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol 2004; 22(14 suppl):248 (Abstract 3513).
26. Díaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005; 23(16 suppl):254s (Abstract 3535).
27. Dakhil S, Cosgriff T, Headley D, et al. Cetuximab + FOLFOX6 as first line therapy for metastatic colorectal cancer (an International Oncology Network study, I-03-002). J Clin Oncol 2006; 24(18 suppl):160s (Abstract 3557).
28. Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Presented at: the 2006 ASCO Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, CA. Abstract 237.
29. Sobrero AF, Fehrenbacher L, Rivera F, et al. Randomized phase III trial of cetuximab plus irinotecan vs irinorecan alone for metastatic colorectal cancer (mCRC) after failing prior oxaliplatin-based therapy: the EPIC trial. Presented at: the 2007 Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract LB2.
30. Polikoff J, Mitchell EP, Badarinath S, et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol 2005; 23(16 suppl):264s (Abstract 3574).
31. Saltz LB, Lenz H-J, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557-61.
32. Hecht JR, Chidiac T, Mitchell E, et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Proceedings of the 9th World Congress on Gastrointestinal Cancer. Ann Oncol 2007; 18:vii21 (Abstract 0-0033).
33. Lievre A, Bachet J-B, Le Corre D, et al. KRAS Mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5.
34. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914-21.
35. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-86.
36. Francoual M, Etienne-Grimaldi MC, Formento JL, et al. EGFR in colorectal cancer: more than a simple receptor. Ann Oncol 2006; 17:962-7.
37. Yatabe Y, Mitsudomi T, Cao L, et al. Correlation of ErbB/HER receptor expression and dimerization patterns as measured by a proximity-based assay using formalin-fixed, paraffin-embedded specimens with clinical response in a cohort of non-small-cell lung cancer patients treated with gefitinib. Presented at the AACR-EORTC meeting; November 14-15, 2005; Philadelphia, PA. Abstract 123.
38. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11:793-814.
39. Adams TE, McKern NM, Ward CW. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 2004; 22:89-95.
40. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-101.
41. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
42. Saltz L, Clark S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX ot FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Presented at: the 2007 Gastrointestinal Cancers Symposium 2007; January 19-21, 2007; Orlando, FL. Abstract 238.
43. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 studies. J Clin Oncol 2005; 23(16 suppl):249s (Abstract 3515).
44. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology™ Colon Cancer. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/colon.pdf. Accessed: October 18, 2007.
45. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-14.
46. Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005; 11:397-405.